Compare WGS & HYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WGS | HYT |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | United States |
| Employees | 1300 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Finance Companies |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | N/A | N/A |
| Metric | WGS | HYT |
|---|---|---|
| Price | $49.52 | $8.54 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $120.71 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 757.2K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.61% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.98 | N/A |
| Revenue Next Year | $25.92 | N/A |
| P/E Ratio | $1,251.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.21 | $8.22 |
| 52 Week High | $170.87 | $9.88 |
| Indicator | WGS | HYT |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 46.99 |
| Support Level | $32.21 | $8.38 |
| Resistance Level | $96.34 | $8.70 |
| Average True Range (ATR) | 3.68 | 0.06 |
| MACD | 1.51 | -0.01 |
| Stochastic Oscillator | 94.11 | 51.56 |
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
BlackRock Corporate High Yield Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide shareholders with current income. The trust's secondary investment objective is to provide shareholders with capital appreciation. Under Normal market conditions, the fund invests at least 80% of its net assets in high-yield securities of corporate issuers and derivatives that provide exposure to those securities or related market risk factors.